Ontology highlight
ABSTRACT: Introduction and importance
The feasibility of combined tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer (MIBC) remains to be investigated.Case presentation
The neoadjuvant treatment not only shrunk tumours significantly but also lowered their stages from T4bN1M0, T3N0M0, and T3bN0M0 to pT1, pT0 and pTis, respectively. The treatment suppressed tumour cell proliferation and promoted luminal-to-basal transition.Clinical discussion
MIBC is an aggressive bladder cancer with poor prognosis. All three patients with MIBC benefited greatly from the neoadjuvant regimen (tislelizumab + gemcitabine + cisplatin). It appears that the effect of the treatment is independent of the levels of programmed death-ligand 1 nor the subtype of urothelial bladder cancer.Conclusion
Combination of tislelizumab with gemcitabine and cisplatin appeared to be a safe and efficacious neoadjuvant therapy for MIBC.
SUBMITTER: Wang Z
PROVIDER: S-EPMC10783357 | biostudies-literature | 2024 Jan
REPOSITORIES: biostudies-literature
Wang Ze Z Wang Yapeng Y Wang Shuo S Ran Qiang Q Peng Song S Zhang Yao Y Zhang Jun J Zhang Dianzheng D Wang Luofu L Lan Weihua W Liu Qiuli Q Jiang Jun J
Annals of medicine and surgery (2012) 20231120 1
<h4>Introduction and importance</h4>The feasibility of combined tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer (MIBC) remains to be investigated.<h4>Case presentation</h4>The neoadjuvant treatment not only shrunk tumours significantly but also lowered their stages from T4bN1M0, T3N0M0, and T3bN0M0 to pT1, pT0 and pTis, respectively. The treatment suppressed tumour cell proliferation and promoted luminal-to-basal transition.<h4>Clinical dis ...[more]